Tobira chairman’s dinner with Brent: Industry chat led to a 3-month pursuit and a stunning $1.7B deal

It started with dinner last summer in New York.

Brent Saunders, Allergan

Brent Saunders, Allergan

Allergan CEO Brent Saunders broke bread with Tobira Chairman Dennis Podlesak and a board member, Domain’s Eckard Weber on June 21. Sometime before the dessert cart rolled, the conversation turned from various industry topics to Tobira’s lead drug.

It ended a few days ago, after Saunders was repeatedly prodded to keep upping an offer to buy the company, starting at $310 million in cash and $740 million in contingent value rights. And even though the lead NASH drug subsequently failed a key study, Saunders eventually jumped into a bidding war for Tobira, agreeing to pay a jaw-dropping premium to bag the biotech for $595 million and a CVR package worth $1.1 billion.

Tobira Chairman Dennis Podlesak

Tobira Chairman Dennis Podlesak

The back-and-forth, spelled out in SEC documents, helps illustrate just how high an active bidder will go for an asset when they decide to master an auction. The closing amount alone reflected a 518% premium over the closing price September 16, the biggest premium many analysts had ever witnessed. And the cash price was close to twice the stock’s 52-week high, a figure that had been blasted by the trial failure.

In this case, Allergan also went a step beyond the usual, offering to sign up key execs on new contracts. And the execs also did well with their final buyout packages. CEO Laurent Fischer grabbed a $6.3 million golden parachute on his way to a $51 million cash-out.

Tobira owes a lot to a company identified only as “Party A” in the SEC docs. Originally interested in a partnership a couple of years ago, Party A would eventually offer $550 million in cash plus $1.05 billion for a CVR to acquire Tobira. And that offer set the stage for Allergan’s best and final offer.

The biotech’s cenicriviroc flunked a Phase IIb study for NASH in July, but the South San Francisco-based biotech said it got enough positive data on a secondary endpoint to warrant a move into a pivotal Phase III program.

Saunders clearly agreed on that point.

via AndyBiotech




The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->